Cytolethal distending toxin subunit B conjugated or fused to Bacillus anthracis toxin lethal factor

Patent metadata

Field	Value
Publication number	US-9890369-B2
Application number	US-201414898248-A
Country	US
Kind code	B2
Filing date	Jun 19, 2014
Priority date	Jun 20, 2013
Publication date	Feb 13, 2018
Grant date	Feb 13, 2018

Abstract

Disclosed is a protein comprising a cytolethal distending toxin subunit B (CdtB) conjugated or fused to a Bacillus anthracis toxin lethal factor (LF) or a functional portion of LF. Related chimeric molecules, as well as related nucleic acids, recombinant expression vectors, host cells, populations of cells, pharmaceutical compositions, methods of treating or preventing cancer, and methods of inhibiting the growth of a target cell are also disclosed.

First claim

The invention claimed is:

1. A protein comprising a cytolethal distending toxin subunit B (CdtB) conjugated or fused to a Bacillus anthracis toxin lethal factor (LF) or a functional portion of LF.

2. The protein of claim 1 , wherein the CdtB is Haemophilus ducreyi CdtB.

3. The protein of claim 1 , wherein the CdtB comprises SEQ ID NO: 1.

4. The protein of claim 1 , wherein the LF or functional portion thereof comprises SEQ ID NO: 2.

5. The protein of claim 1 , wherein the protein comprises SEQ ID NO: 3.

6. A chimeric molecule comprising (a) (i) a targeting moiety, (ii) a Bacillus anthracis protective antigen (PA), or (iii) both (i) and (ii) conjugated or fused to (b) the protein of claim 1 .

7. The chimeric molecule according to claim 6 , wherein the PA is wild-type PA (wtPA), PA-L1, PA-U2, PA-U7, PA-D512K, PA-GN, PA-NS, PA-R200A, or PA-I210A.

8. The chimeric molecule of claim 6 , wherein the targeting moiety is a monoclonal antibody, antigen-binding portion of an antibody, peptide, hormone, growth factor, or cytokine.

9. The chimeric molecule of claim 8 , wherein the targeting moiety is a monoclonal antibody or an antigen binding portion thereof.

10. The chimeric molecule of claim 9 , wherein the monoclonal antibody or antigen binding portion thereof specifically binds to a cell surface marker selected from the group consisting of CD19, CD21, CD22, CD25, CD30, CD33, CD79b, CD123, epidermal growth factor receptor variant III (EGFRvIII), interleukin-15 receptor, interleukin-8 receptor, interleukin-2 receptor, transferrin receptor, epidermal growth factor (EGF) receptor, mesothelin, cadherin, Lewis Y, vascular endothelial growth factor (VEGF) receptor, HER2, estrogen receptor, carcinoembryonic antigen, prostate-specific membrane antigen, prostate-specific antigen, interleukin (IL)-13 receptor, IL-4 receptor, IL-3 receptor, granulocyte-macrophage colony-stimulating factor (GM-CSF) receptor, CD4, gp160, gp120, HIV-1 gag (p24), and gp41.

11. The chimeric molecule of claim 6 , wherein the targeting moiety is an antibody selected from the group consisting of B3, RFB4, SS, HN1, HN2, and antigen binding portions thereof.

12. A nucleic acid comprising a nucleotide sequence encoding the protein of claim 1 .

13. A pharmaceutical composition comprising (a) the protein of claim 1 and (b) a pharmaceutically acceptable carrier.

14. The pharmaceutical composition of claim 13 , further comprising one or more PAs.

15. The pharmaceutical composition of claim 14 , wherein the one or more PAs comprise any one or more of wtPA, PA-L1, PA-U2, PA-U7, PA-D512K, PA-GN, PA-NS, PA-R200A, and PA-I210A.

16. The pharmaceutical composition of claim 14 , wherein the one or more PAs are conjugated or fused to a targeting moiety.

17. A method of producing the protein of claim 1 , the method comprising (a) recombinantly expressing the protein and (b) purifying the protein.

18. A method of producing the chimeric molecule of claim 6 comprising (a) recombinantly expressing the chimeric molecule and (b) purifying the chimeric molecule.

19. A method of producing a chimeric molecule comprising (a) recombinantly expressing the protein of claim 1 , (b) purifying the protein, and (c) covalently linking (i) a PA, (ii) a targeting moiety or (iii) both (i) and (ii) to the purified protein.

20. A method of inhibiting the growth of a target cell, the method comprising contacting the cell with the protein of claim 1 in an amount effective to inhibit growth of the target cell.

Assignees

• Us Health

Inventors

• Bachran Christopher H
• Leppla Stephen H

Classifications

• C07K14/32

  from Bacillus (G) · CPC title

• A61K38/4886

  Metalloendopeptidases (3.4.24), e.g. collagenase · CPC title

• C12Y304/24083

  Anthrax lethal factor endopeptidase (3.4.24.83) · CPC title

• A61K38/164

  from bacteria · CPC title

• C07K14/285

  from Pasteurellaceae (F), e.g. Haemophilus influenza · CPC title